This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Starlix

Novartis AG

Drug Names(s): nateglinide, YM026 , nategurinide; Fastic; Starsis; Trazec

Description: Starlix (Nateglinide) is an oral antidiabetic agent that belongs to a class of drugs called meglitinides. Nateglinide stimulates cells in the pancreas to produce insulin in a manner similar to the class of drugs called sulfonylureas which also are used in type 2 diabetes. However, Nateglinide appears to have a faster onset and a shorter duration of action than sulfonylureas. The benefit of this faster, shorter effect may be to prevent the rapid, transient rise in blood glucose that occurs in diabetics immediately following a meal.

Deal Structure: Novartis holds exclusive development and marketing rights from Ajinomoto outside South East Asia, except for the UK and the Republic of Ireland. Ajinomoto co-developed the drug with Yamanouchi and Morishita in Japan. On April 1, 2005, Astellas Pharma was formed from a merger between Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.

Partners: Astellas Pharma, Inc. Ajinomoto Pharmaceuticals Co., Ltd.


Starlix News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug